prospectively ascertained

2 trials

Sponsors

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie; Charité Universitätsmedizin, Pharmakoivigilanz- und Beratungszentrum für Embryonaltoxikologie, Charité Berlin

Conditions

P04.1foetal methotrexate syndrome, congenital malformations, spontaneous abortions after intrauterine methotrexate exposure. MedDRA - 10071184 (LLT, 14.1): Foetal methotrexate syndrome Q86.8

Unknown Phase

Is there an increased risk for adverse pregnancy outcome after exposure to low-dose methotrexate (MTX) during early pregnancy? A prospective multicenter cohort study.

Active, not recruitingDRKS00003328

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie; Charité Universitätsmedizinfoetal methotrexate syndrome, congenital malformations, spontaneous abortions after intrauterine methotrexate exposure. MedDRA - 10071184 (LLT, 14.1): Foetal methotrexate syndrome Q86.8

Start: 2012-02-06Target: 1450Updated: 2025-04-07

The safety of anti-tumor necrosis factor-alpha (TNF-a) agents in pregnancy. An observational prospective multicenter study.

Active, not recruitingDRKS00005036

Pharmakoivigilanz- und Beratungszentrum für Embryonaltoxikologie, Charité BerlinP04.1

Start: 2013-09-02Target: 1837Updated: 2025-04-07